Yuji Yamazaki

Dr. Yuji Yamazaki

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Proceedings of the Japan Academy, Series B
Verified
Journal Article
Open access
PDF file
YSYutaka Seino Yutaka Seino
Yutaka Seino Yutaka Seino
YYYuji Yamazaki
Yuji Yamazaki
It is now accepted that the pathogenesis of type 2 diabetes in East Asians including Japanese differs distinctly from that in Caucasians. Many non-obese individuals in Japan develop type 2 diabetes and present clinically with insufficient insulin secretion rather than a large increase in the insulin resistance. To understand the pathophysiology of this non-obese diabetes, we studied Goto-Kakizaki rats, a unique model of spontaneous non-obese diabetes, and identified mitochondrial dysfunction in pancreatic β-cells as a factor in decreased insulin secretion. Looking for a clinical treatment option, we focused on the incretins because of their glucose-dependent insulin stimulatory effect. Our findings have contributed to the understanding of incretin action and the development of incretin-associated therapeutics and shed light on the nature of East Asian diabetes and its optimal clinical treatment.

28 August 2024 in Diabetes
Verified
Journal Article
Closed access
PDF file
THTakuya Haraguchi
Takuya Haraguchi
YYYuji Yamazaki
Yuji Yamazaki
HKHitoshi Kuwata
Hitoshi Kuwata
RURyota Usui
Ryota Usui
YHYoshiyuki Hamamoto
Yoshiyuki Hamamoto
YYYuichiro Yamada
Yuichiro Yamada
Evaluation of insulin secretory capacity is essential to understand the pathophysiologic condition of individuals with diabetes and assess the efficacy of drugs used in the treatment of this disease. The 1-mg i.v. glucagon stimulation test (GST) is widely used to evaluate residual β-cell function; we previously reported that GST assessment of insulin secretory capacity is useful in assessing the efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs). However, recent reports have indicated that pharmacologic concentrations of glucagon stimulate insulin secretion through GLP-1 receptors, confounding the issue. The current studies were undertaken to reassess the reliability of the GST for evaluation of insulin secretory capacity under GLP-1RAs and dipeptidyl peptidase 4 inhibitors (DPP-4is). Our first study included individuals receiving GLP-1RA treatment, evaluated by the GST before and after treatment. Although the fasting C-peptide response (CPR) levels were elevated after treatment, the induction of insulin secretion by glucagon was significantly reduced. Our second study compared glucagon-induced insulin secretion between DPP-4i users and nonusers, assessed by the GST after propensity score matching. Although the fasting CPR levels were similar in the two investigations, glucagon-induced insulin secretion was significantly lower with DPP-4i use. These results suggest that the GST might underestimate insulin secretory capacity under incretin-based therapy. Article Highlights:

22 July 2025 in Diabetologia
Verified
Journal Article
Closed access
PDF file
YYYuko Yamaguchi
Yuko Yamaguchi
HKHitoshi Kuwata
Hitoshi Kuwata
MIMasahiro Imura
Masahiro Imura
SMShota Moyama
Shota Moyama
RURyota Usui
Ryota Usui
YYYuji Yamazaki
Yuji Yamazaki

23 September 2020 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
PDF file
YFYuki Fujita
Yuki Fujita
DTDaisuke Tanaka
Daisuke Tanaka
HTHisato Tatsuoka
Hisato Tatsuoka
MMMiho Matsubara
Miho Matsubara
THTakanori Hyo
Takanori Hyo
YYYuji Yamazaki
Yuji Yamazaki
Summary Maturity-onset diabetes of the young (MODY) is a form of monogenic diabetes mellitus characterised by early onset and dominant inheritance. Delayed diagnosis or misdiagnosis as type 1 or type 2 diabetes mellitus is common. Definitive genetic diagnosis is essential for appropriate treatment of patients with MODY. The hepatocyte nuclear factor 1-beta (HNF1B) gene is responsible for MODY type 5 (MODY5), which has distinctive clinical features including renal disease. MODY5 should always be considered by clinicians in patients with early onset diabetes and renal anomalies. We report a case of a 30-year-old Japanese male with early-onset diabetes mellitus, renal anomalies and family history of diabetes that was suggestive of MODY5. Renal histology showed no evidence of diabetic nephropathy. Genetic testing revealed a novel heterozygous splice-site mutation of the HNF1B gene in the family members. It was strongly suggested that the mutation could underlie our patient’s MODY5. Learning points: Genetic diagnosis of MODY is relevant for appropriate treatment. Dominantly inherited early-onset diabetes mellitus with renal cysts suggests MODY5. Scanning the non-coding regions is important for not missing a mutation in HNF1B. Abstract Summary Maturity-onset diabetes of the young (MODY) is a form of monogenic diabetes mellitus characterised by early onset and dominant inheritance. Delayed diagnosis or misdiagnosis as type 1 or type 2 diabetes mellitus is common. Definitive genetic diagnosis is essential for appropriate treatment of patients with MODY. The hepatocyte nuclear factor 1-beta (HNF1B) gene is responsible for MODY type 5 (MODY5), which has distinctive clinical features including renal disease. MODY5 should always be considered by clinicians in patients with early onset diabetes and renal anomalies. We report a case of a 30-year-old Japanese male with early-onset diabetes mellitus, renal anomalies and family history of diabetes that was suggestive of MODY5. Renal histology showed no evidence of diabetic nephropathy. Genetic testing revealed a novel heterozygous splice-site mutation of the HNF1B gene in the family members. It was strongly suggested that the mutation could underlie our patient’s MODY5. Learning points: Genetic diagnosis of MODY is relevant for appropriate treatment. Dominantly inherited early-onset diabetes mellitus with renal cysts suggests MODY5. Scanning the non-coding regions is important for not missing a mutation in HNF1B.

2 February 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
MMMari Matsushiro
Mari Matsushiro
YYYuko Yamaguchi
Yuko Yamaguchi
HKHitoshi Kuwata
Hitoshi Kuwata
YHYoshiyuki Hamamoto
Yoshiyuki Hamamoto
YSYutaka Seino Yutaka Seino
Yutaka Seino Yutaka Seino
YYYuji Yamazaki
Yuji Yamazaki

14 November 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
YYYuji Yamazaki
Yuji Yamazaki
YSYutaka Seino Yutaka Seino
Yutaka Seino Yutaka Seino
GIP is a multifaceted hormone whose role in metabolism is highly context-dependent. Pharmacological GIP receptor activation promotes weight loss and improves insulin sensitivity, contrasting sharply with the lipogenic and insulin-resistant effects of endogenous GIP. However, it remains unclear whether these effects simply amplify endogenous GIP's actions or represent distinct mechanisms.